Advertisement

History and Overview

  • Hans-Georg Rammensee
  • Jutta Bachmann
  • Stefan Stevanović
Part of the Molecular Biology Intelligence Unit book series (MBIU)

Abstract

The traits of MHC genes have been noticed as early as in the beginning of the 20th century: a tumor grafted from a mouse to a genetically different mouse was rejected, whereas a tumor transplanted to a mouse of the same strain was not rejected. Thus, the tumor was not rejected on account of tumor-specific antigens but rather because of genetic differences between the mouse strains involved.1 It was not until 1936, however, that what is now known as the MHC was discovered by Peter Gorer, then in London.2 He had produced a rabbitanti-mouse serum for the sake of blood group studies. The reactivity of this serum, called Nr. II, showed a striking correlation with tumor rejection: a tumor of the mouse strain A was rejected by C57 mice and in a certain proportion of (A × C57)F1 × C57 backcross mice. All mice not reactive with the serum rejected the tumor. On the other hand, those mice rejecting the tumor developed antibodies with the same reactivity as rabbit serum Nr. II. Thus, it appeared that what caused tumor rejection was a blood-group like antigen shared by normal and tumor cells.2 Since this antigen was originally discovered because of its recognition by rabbit anti-mouse serum Nr. II and because it resulted in tumor rejection, it was called histocompatibility antigen 2 or H-2—not immediately, however, but about 10 years later by George Snell and Gorer.1

Keywords

Tumor Rejection Invariant Chain Peptide Motif Peptide Loading Histocompatibility Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Klein J. Natural History of the Major Histocompatibility Complex. New York: J. Wiley and Sons; 1986.Google Scholar
  2. 2.
    Gorer PA. The genetic and antigenic basis of tumor transplantation. J Pathol Bacteriol 1937; 44: 691–7.CrossRefGoogle Scholar
  3. 3.
    Graff RJ, Snell GD. Histocompatibility genes of mice. 8. The alleles of the H-1 locus. Transplantation 1968; 6: 598–617.PubMedCrossRefGoogle Scholar
  4. 4.
    Counce S, Smith P, Barth R et al. Strong and weak histocompatibility gene differences in mice and their role in the rejection of homografts of tumors and skin. Ann Surg 1956; 144: 198–204.PubMedCrossRefGoogle Scholar
  5. 5.
    Graff RJ, Polinsky SL, Snell GD. Histocompatibility genes of mice. Transplantation 1971; 11: 56–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Rammensee HG, Klein J. Polymorphism of minor histocompatibility genes in wild mice. Immunogenetics 1983; 17: 637–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Dausset J. The challenge of the early days of human histocompatibility. Immunogenetics 1980; 10: 1–5.PubMedCrossRefGoogle Scholar
  8. 8.
    McDevitt HO, Sela M. Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med 1965; 122: 517–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Green I, Paul WE, Benacerraf B. Genetic control of immunological responsiveness in guinea pigs to 2,4-dinitrophenyl conjugates of poly-L-arginine, protamine, and poly-L-ornithine. Proc Natl Acad Sci USA 1969; 64: 1095–102.PubMedCrossRefGoogle Scholar
  10. 10.
    McDevitt HO, Chinitz A. Genetic control of the antibody response: relationship between immune response and histocompatibility (H-2) type. Science 1969; 163: 1207–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Kindred B, Shreffler DC. H-2 dependence of co-operation between T and B cells in vivo. J Immunol 1972; 109: 940–3.PubMedGoogle Scholar
  13. 13.
    Mishell RI, Dutton RW. Immunization of normal mouse spleen cell suspensions in vitro. Science 1966; 153: 1004–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Brunner KT, Mauel J, Cerottini JC et al. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968; 14: 181–96.PubMedGoogle Scholar
  15. 15.
    Klein J. The major histocompatibility complex of the mouse. Science 1979; 203: 516–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Bevan MJ. In a radiation chimaera, host H-2 antigens determine immune responsiveness of donor cytotoxic cells. Nature 1977; 269: 417–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Nagy Z, Klein J. Macrophage or T cell-that is the question. Immunol Today 1981; 2: 228–229.CrossRefGoogle Scholar
  18. 18.
    Shevach E. Is determinant selection dead? Immunol Today 1982; 3: 31–34CrossRefGoogle Scholar
  19. 19.
    Hedrick SM, Cohen DI, Nielsen EA et al. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 1984; 308: 149–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Yanagi Y, Yoshikai Y, Leggett K et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 1984; 308: 145–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Shimonkevitz R, Kappler J, Marrack P et al. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med 1983; 158: 303–16.PubMedCrossRefGoogle Scholar
  22. 22.
    Allen PM, Strydom DJ, Unanue ER. Processing of lysozyme by macrophages: identification of the determinant recognized by two T-cell hybridomas. Proc Natl Acad Sci U S A 1984; 81: 2489–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Unanue ER. Cooperation between mononuclear phagocytes and lymphocytes in immunity. N Engl J Med 1980; 303: 977–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985; 42: 457–67.PubMedCrossRefGoogle Scholar
  25. 25.
    Townsend AR, Rothbard J, Gotch FM et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44: 959–68.PubMedCrossRefGoogle Scholar
  26. 26.
    Steinmetz M, Frelinger JG, Fisher D et al. Three cDNA clones encoding mouse transplantation antigens: homology to immunoglobulin genes. Cell 1981; 24: 125–34.PubMedCrossRefGoogle Scholar
  27. 27.
    Orr HT, Lopez de Castro JA, Lancet D et al. Complete amino acid sequence of a papain-solubilized human histocompatibility antigen, HLA-B7. 2. Sequence determination and search for homologies. Biochemistry 1979; 18: 5711–20.Google Scholar
  28. 28.
    Henning R, Milner RJ, Reske K et al. Subunit structure, cell surface orientation, and partial amino-acid sequences of murine histocompatibility antigens. Proc Natl Acad Sci U S A 1976; 73: 118–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Bjorkman PJ, Saper MA, Samraoui B et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Bjorkman PJ, Davis MM. Model for the interaction of T-cell receptors with peptide/MHC complexes. Cold Spring Harbor Symp Quant Biol 1989; 54: 365–74.PubMedCrossRefGoogle Scholar
  31. 31.
    Rötzschke O, Falk K, Wallny HJ et al. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 1990; 249: 283–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Rötzschke O, Falk K, Deres K et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990; 348: 252–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Falk K, Rötzschke O, Stevanovï S et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Madden DR, Gorga JC, Strominger JL et al. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991; 353: 321–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Fremont DH, Matsumura M, Stura EA et al. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb [see comments]. Science 1992; 257: 919–27.PubMedCrossRefGoogle Scholar
  36. 36.
    Rudensky AY, Preston Hurlburt P, Hong SC et al. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Hunt DF, Michel H, Dickinson TA et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992; 256: 1817–20.PubMedCrossRefGoogle Scholar
  38. 38.
    Chicz RM, Urban RG, Gorga JC et al. Specificity and promiscuity among naturally processed peptides bound to HLADR alleles. J Exp Med 1993; 178: 27–47.PubMedCrossRefGoogle Scholar
  39. 39.
    Falk K, Rötzschke O, Stevanovic S et al. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 1994; 39: 230–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Jardetzky TS, Gorga JC, Busch R et al. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J 1990; 9: 1797–803.PubMedGoogle Scholar
  41. 41.
    Hammer J, Valsasnini P, Tolba K et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993; 74: 197–203.PubMedCrossRefGoogle Scholar
  42. 42.
    Hammer J, Takacs B, Sinigaglia F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 1992; 176: 1007–13.PubMedCrossRefGoogle Scholar
  43. 43.
    Brown JH, Jardetzky TS, Gorga JC et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 215–21.PubMedCrossRefGoogle Scholar
  45. 45.
    Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today 1993; 14: 349–52.PubMedCrossRefGoogle Scholar
  46. 46.
    Dick TP, Ruppert T, Groettrup M et al. Coordinated dual cleavages induced by the proteasome regulator P28 lead to dominant MHC ligands. Cell 1996; 86: 253–62.PubMedCrossRefGoogle Scholar
  47. 47.
    Sadasivan B, Lehner PJ, Ortmann B et al. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996; 5: 103–114PubMedCrossRefGoogle Scholar
  48. 48.
    Lammert E, Stevanovie S, Brunner J et al. Protein disulfide isomerase is the dominant acceptor for peptides translo- cated into the endoplasmic reticulum. [In Press] Eur J Immunol.Google Scholar
  49. 49.
    Arnold D, Faath S, Rammensee HG et al. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 1995; 182: 885–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269: 1585–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Lammert E, Arnold D, Nijenhuis M et al. The endoplasmic reticulum-resident stress protein gp96 binds peptides trans-located by TAP. Eur J Immunol 1997; 27: 923–927.PubMedCrossRefGoogle Scholar
  52. 52.
    Hughes EA, Ortmann B, Surman M et al. The protease inhibitor, N-acetyl-Lleucyl-L-leucyl-leucyl-L-norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum. J Exp Med 1996; 183: 1569–78.PubMedCrossRefGoogle Scholar
  53. 53.
    Schekman R. Polypeptide Translocation: A Pretty Picture Is Worth a Thousand Words. Cell 1996; 87: 593–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Wiertz EJ, Jones TR, Sun L et al. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996; 84: 769–79.PubMedCrossRefGoogle Scholar
  55. 55.
    Riese RJ, Wolf PR, Bromme D et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996; 4: 357–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • Hans-Georg Rammensee
    • 1
  • Jutta Bachmann
    • 1
  • Stefan Stevanović
    • 1
  1. 1.University of TübingenTübingenGermany

Personalised recommendations